Corvidane is developing Corvida™ to treat TWO formidable diseases. Corvidane uses a novel approach to treat metabolic and inflammatory diseases. Corvida(TM) for Atherosclerosis - In development to be a Best-in-Class, orally administered adjunct to lipid regulating therapies (Statins/PCSK9) that targets atherosclerotic plaques, the major factor in Heart Attacks and Stroke. Corvida(TM) for MASH - In development to be a Best-in-Class, orally administered drug to treat MASH, which is the leading cause of liver transplants in the United States.
| Website | http://www.corvidane.com |
| Employees | 4 (3 on RocketReach) |
| Founded | 2014 |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Atherosclerosis Treatment, Drug Development, Pharmaceutical Research, Therapeutic Innovation, Clinical Development, Drug Discovery, Treatment Development, Pharmaceutical, Biotechnology, Medical Research, Disease Treatment, Biopharma |
Looking for a particular Corvidane employee's phone or email?
Corvidane Questions
Damion Boyer is the Co-Founder of Corvidane.
3 people are employed at Corvidane.
Top Corvidane Employees
-
Damion Boyer
Co-Founder at Corvidane
Netherlands44 -
Patrice Binay
VP Cmc chemistry manufacturing and controls at Corvidane
Inzinzac-Lochrist, FR1 -
Sarah Torri
Clinical Development Advisor at Corvidane
Chicago, IL, US12
Related Companies
